INOVIO

DNA MEDICINE:
HARNESSING THE POWER OF *IN VIVO* PROTEIN PRODUCTION

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to fight HPV-related diseases, cancer and infectious diseases. We use proprietary technology to design DNA plasmids — small circular DNA molecules that work like software the body's cells can download to produce specific proteins to target and fight disease. Our proprietary investigational CELLECTRA® devices are designed to deliver the plasmids into the body's cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors.

Optimized design and delivery, teaching the body to fight disease



Targeted Therapies, T Cell Driven Immune Responses

INOVIO can design plasmids to teach the body's cells to produce a wide range of proteins, including antigens to elicit a specific immune response, monoclonal antibodies to fight a specific pathogen, or therapeutic proteins to replace defective or missing proteins in the body. Our versatile platform is able to generate antigen-targeted humoral and cellular immune responses, including antigen-specific cytotoxic or killer T cell responses that are important for fighting cancer and viral infections.

INVESTMENT HIGHLIGHTS

- INO-3107 BLA accepted for review under accelerated approval program in Dec 2025; PDUFA date set for Oct 30, 2026
- Commercial preparations for INO-3107 underway to be ready to launch efficiently if approved
- Pipeline advancement through collaborations & strategic partnerships:
  - New collaboration with Akeso to evaluate INO-5412 in combination with cadonilimab for potential treatment of GBM
  - Phase 2 trial sponsored by Dana-Farber Cancer Institute

Our Pipeline: Advancing DNA Medicine

We are advancing DNA medicine candidates with the potential to transform disease prevention and treatment paradigms and improve patients' lives. In our clinical trials conducted to date, our DNA medicine candidates have been well tolerated and shown a favorable safety profile while demonstrating the ability to induce robust immune responses. They can be re-administered, allowing for their use as primary vaccinations and long-term therapies.

INOVIO's Biologics License Application (BLA) for INO-3107 as a potential treatment for RRP has been under active review by the FDA since December 2025 when the Agency accepted the file under the accelerated approval program. The Prescription Drug User Fee Act (PDUFA) target date is October 30, 2026. In late April 2026, the FDA conducted its mid-cycle review of the BLA, raising no new significant issues. INOVIO is focused on advancing INO-3107 through the regulatory process and working with the FDA as they complete their review of the BLA, including addressing the potential review issue they noted in their file acceptance letter regarding eligibility for review under the accelerated approval program. INOVIO continues to strongly believe that INO-3107 fulfills the criteria for accelerated approval, meeting a significant unmet need and providing a meaningful therapeutic benefit over existing treatments.

CURRENT DEVELOPMENT STATUS OF INOVIO ASSETS

MULTIPLE CLINICAL TRIALS UNDERWAY, SEVERAL CONDUCTED BY PARTNERS



*BLA accepted for review under accelerated approval program in Dec 2025 with a target PDUFA date of Oct 2026 **VGX-3100 to Apollo Bio for China

SNAPSHOT: BUILDING ON EXPERIENCE IN HPV

A growing body of clinical research points to the potential of DNA medicines to change treatment paradigms, particularly for HPV-related diseases where targeted cytotoxic T cell responses are needed to clear HPV-infected cells.



LEARN MORE:
INOVIO.COM

MEDIA | communications@inovio.com
INVESTOR RELATIONS | investor.relations@inovio.com